New biologic XmAb657 enters first human tests for autoimmune conditions
NCT ID NCT07284797
First seen Jan 06, 2026 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handles the drug. Participants receive the drug as an injection under the skin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Xencor Investigative Site
RECRUITINGMelbourne, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XmAb657 (a biologic drug given as an injection under the skin)
What this could lead to
If successful, this could lead to a new treatment option for certain autoimmune diseases like scleroderma and Sjögren's disease.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (60 people) and may not lead to a working treatment. Side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.